Piramal Pharma Solutions’ UK facility bags updated MHRA GMP certification
Grangemouth serves as PPS’s dedicated antibody-drug conjugate development and manufacturing hub
Grangemouth serves as PPS’s dedicated antibody-drug conjugate development and manufacturing hub
Both companies will jointly execute development and scale-up of multiple strategic APIs, including late-stage NCE-1 opportunities
The successful refinancing and enhancement of the syndicated credit facilities provides access to an additional CHF 40 million
The quarter included three IPOs worth US$ 428 million and one Qualified Institutional Placement (QIP) worth US$ 88 million
The antibody was designed and developed at Abzena’s Cambridge, UK,
The new CMC Process R&D Center represents a strategic investment in scale, sustainability, and specialization
Telangana aims to increase the value of the Life Sciences economy from US$ 80 billion to US$ 250 billion by 2030
Expanding US operations to address the increased demand for API development and manufacturing
Subscribe To Our Newsletter & Stay Updated